開胸術後癒着防止への探求: 表層水誘導技術を用いた不溶化ヒアルロン酸膜の開発 by 上村 暁子 & Akiko UEMURA
Study on the Prevention of Postoperative
Pleural Adhesion: Development of an Insoluble
Hyaluronic Acid Membrane Using Surface Water
Induction Technology
著者（英） Akiko UEMURA
内容記述 この博士論文は内容の要約のみの公開（または一部
非公開）になっています
year 2019
その他のタイトル 開胸術後癒着防止への探求: 表層水誘導技術を用い
た不溶化ヒアルロン酸膜の開発
学位授与大学 筑波大学 (University of Tsukuba)
学位授与年度 2018
報告番号 12102甲第9086号
URL http://hdl.handle.net/2241/00156405
 Study on the Prevention of Postoperative 
Pleural Adhesion: Development of an 
Insoluble Hyaluronic Acid Membrane 
Using Surface Water Induction Technology 
 
 
 
 
 
 
 
January 2019 
 
 
 
Akiko UEMURA 
 
Study on the Prevention of Postoperative 
Pleural Adhesion: Development of an 
Insoluble Hyaluronic Acid Membrane 
Using Surface Water Induction Technology 
 
 
 
 
A Dissertation Submitted to  
the Graduate School of Life and Environmental Sciences,                     
the University of Tsukuba 
 in Partial Fulfillment of the Requirements 
for the Degree of Doctor of Philosophy in Agricultural Science 
(Doctoral Program in Bioindustrial Sciences) 
 
 
Akiko UEMURA 
 
ⅰ 
 
【 Contents 】 
Chapter 1 General Introduction  ................................................................................. 1 
Chapter 2 Elucidation of the time-dependent degradation process in insoluble 
hyaluronic acid formulations with a controlled degradation rate  ................................. 10 
Introduction  ............................................................................................................. 10 
Materials and Methods  ............................................................................................ 13 
Results  ..................................................................................................................... 18 
Discussion  ............................................................................................................... 23 
Conclusions  ............................................................................................................. 26 
 
Chapter 3   Development of an Anti-Adhesive Membrane for Use in 
Video-Assisted Thoracic Surgery  ................................................................................. 27 
Introduction  ............................................................................................................. 27 
Materials and Methods  ............................................................................................ 29 
Results  ..................................................................................................................... 34 
Discussion  ............................................................................................................... 42 
Conclusions  ............................................................................................................. 46 
 
Chapter 4 Utility of lung ultrasound for detection of pleural adhesions in dogs ....... 47 
Introduction  ............................................................................................................. 47 
Materials and Methods  ............................................................................................ 50 
Results  ...................................................................................................................... 57 
Discussion  ............................................................................................................... 60 
Conclusions  ............................................................................................................. 64 
 
 
ⅱ 
 
Chapter 5 General Discussion .................................................................................... 65 
Conclusions  .............................................................................................................. 75 
References .................................................................................................................. 78 
Acknowledgement ..................................................................................................... 92 
Abstract  .................................................................................................................... 94 
 
 1 / 98 
 
 
Chapter 1 
General Introduction 
The Needs of Effective New Membrane for Preventing Postoperative Pleural 
Adhesion and The Reason for Choosing Hyaluronic Acid as Material Membrane
 
Post-operative adhesions occur at a high rate. Organ damage such as abdominal pain, 
intestinal obstruction and infertility occurs after an abdominal surgery due to peritoneal 
adhesion (1, 2), and its harmful effects have been known widely. It is reported that this 
abdominal postoperative adhesion occurs not only in laparotomy, but also in an 
endoscopic surgery (3). On the other hand, post-thoracotomy adhesion also occurs at 
high rate, but its relevance to organ damage has not been well described. Although 
post-operative risk of damage to the heart and large vessels (4) has been reported, few 
reports mentioned the problems related to the quality of life of postoperative patients, 
and the level of general awareness of these complications is low. However, it is known 
as an important problem in thoracic surgery that post-thoracotomy adhesions cause 
serious harmful effects during re-operation of the chest. This is because adhesions of the 
chest wall, lungs and pericardium cause problems such as extended re-operation time, 
bleeding, inadequate view of the surgical field and pulmonary vascular injury (5-9). 
 2 / 98 
 
 
To prevent post-abdominal operative adhesion, adhesion prevention membrane, 
mainly composed of carboxymethyl-cellulose, has become commercially available, and 
is reported to reduce post-abdominal operative adhesion effectively (10-13). Some 
reports also that suggest that this carboxymethyl-cellulose membrane was significantly 
effective in preventing adhesion in pediatric cardiac surgery (14) and rat 
mediastinoscopy examination (15). When it was applied to thoracic surgery. There are 
multiple methods using carboxymethyl-cellulose membrane for laparoscopy, including 
the one using (16-18) membrane cut into several small pieces to wrap around the 
forceps, and others with the reported efficacy of the carboxymethyl-cellulose membrane 
in laparoscopy (19, 20). 
On the other hand, the need of preventing post-thoracotomy adhesion has been 
recognized so far which is regarded as one of the important factor in thoracic surgery. 
Many prevention methods have been studied for a long time (21-24), and all of them are 
still under the development stage and has not reached commercially available stage yet. 
Another type of post-operative adhesion prevention membrane using surface water 
induction technology is that is more effective than carboxymethyl-cellulose membrane, 
which is primarily comprised of glycerin with has a high water retention capacity, and it 
was reported to be used in dogs already (25). However, multiple risks of hemolysis that 
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may occur in the body due to glycerin have been reported (26, 27), and glycerine has a 
safety-related concern as an in vivo preparation. Therefore, it is necessary to develop a 
post-thoracotomy adhesion inhibitor with superior safety and efficacy using surface 
water induction technology, by switching the water-retentive compound to an in vivo 
absorptive substance with higher safety than that of glycerin.  
Hyaluronic acid was discovered by Meyer as a vitreous component of bovine 
eyeball in 1934 (28) and is a type of glycosaminoglycan (29). Hyaluronic acid is 
distributed extensively in cartilage, skin, and joints as extracellular matrix in the body. 
Hyaluronic acid with high water retentivity contributes to the stability, lubricity and 
elasticity of tissues (30), and is a component having many physiological activities in the 
body. For its usefulness, hyaluronic acid is widely used as medicine including 
therapeutic agents for osteoarthritis such as shoulder joints (31) and knee joints (32, 33), 
anti-adhesion agents for post- abdominal operation (34, 35), as a filler (36, 37) in plastic 
surgery and cosmetic care. To fit these various applications, demand for hyaluronic acid 
to display more features as a medical product has been increasing. In particular, 
controlling its rates of degradation and absorption represents a significant challenge. 
This is because the material remaining in the body for the required amount of time and 
exhibiting its effects continuously; would result in more stable control of various 
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diseases. How hyaluronic acid formulations degrad, in addition to the degradation rate 
itself, is also an important factor. For example, does the material retain its form until 
just before degradation? Or does it gradually degrade from the begining? This 
difference would become a critical point when investigating its effect on a target disease 
or site. 
Adjustment of properties and the degradation rate of hyaluronic acid is also 
performed by changing the molecular weight (38) and by using crosslinkers (39) (40). 
However, these methods have some issues left unsolved, especially safety of byproducts. 
On the other hand, my research collaborator founded the methods of treatment for 
hyaluronic acid using acetic anhydride (unpublished data). The method for 
insolubilization of hyaluronic acid, in accordance with the method described in previous 
reference (41). It is known that polysaccharide reacts with acid and produces an 
insolubles. For example, one of polysaccharides sodium alginate is used as a curative 
medicine to a regurgitant esophagus flame (42). Preliminary experiment was performed 
using this characteristic, hyaluronic acid was reacted with several acid. Good results 
were obtained by the reaction of acetic anhydride. Thus acetic anhydride was used for 
insolubilization of hyaluronic acid in this study. 
Based on these findings, treatment for hyaluronic acid using acetic anhydride was 
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focused. The changing ratio were investigated the treatment time, insolubilization rate, 
and swelling ratio. In addition, the relationship between these ratio and degradable with 
decomposition behavior in thie study. Eventually, the present study aims to develop a 
new post-thoracotomy adhesion prevention membrane using insoluble hyaluronic acid 
as a water-retentive substance that can replace glycerin, with developmental processes 
consisting the following three steps. That is inspection of hyaluronic acid as advanced 
materials for a water-retentive substance, effect as anti-adhesive membrane and the 
research for the detection method of the pleural adhesion. 
 In Chapter 2 the properties of in hyaluronic acid required to be used as a 
post-operative adhesion inhibitor was verified. The post-operative adhesion inhibitor 
must remain in the surgical invasion sites such as incisional wound for about 7 days 
when adhesions are formed and must physically prevent such adhesion formation. 
Therefore, the hyaluronic acid preparation as a post-operative adhesion inhibitor must 
remain in the insertion site for a certain period of time to exhibit its effect, without 
being absorbed immediately after being inserted into the body. However, the factors that 
control the decomposition rate of hyaluronic acid are still unknown. If the unknown 
factors capable of controlling the decomposition rate of hyaluronic acid can be clarified, 
its utility value will be infinitely large. Another important factor to consider is how 
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many byproducts will be produced, and what kind of decomposition process will be 
encountered by this new hyaluronic acid preparation during its production process that 
utilizes the aforementioned unknown factors. Although hyaluronic acid has been 
reported to change its decomposition rate depending on the rise and fall of its swelling 
rate, the factors controlling the swelling rate itself are have not been clarified yet (43). 
Therefore, the following experiments were conducted in Chapter 2. First, three types of 
hyaluronic acid preparations were prepared with different swelling ratios and the 
decomposition processes unaffected by enzymes were examined. The changes during 
the hyaluronic acid preparation inside a simulated body fluid were measured and scored 
based on the swelling ratio.  
In Chapter 3, using a dog open thoracotomy model, the chest post-thoracotomy 
adhesion prevention effect and the operability of insoluble hyaluronic acid membrane 
were investigated, of which decomposition process was elucidated in Chapter 2. 
Post-thoracotomy adhesion is a significant problem during re-operation. Although 
re-operation rate in thoracic surgery depends on the disease, chest re-operation is 
considered to be one of the common treatment options for treating metastasis or 
recurring malignant tumor (44-46). Re-operation rate in aortic valve replacement and 
coronary artery bypass surgery is 10% to 20% (46), and multiple operations are 
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common for children with congenital heart disease (47, 48). In recent years, VATS 
(Video-Assisted Thoracic Surgery) using a thoracoscope has been developed and is 
generally recognized as a minimally invasive treatment. The application of VATS on 
various diseases mainly in respiratory surgery and cardiac surgery has been expanding, 
and there is also a great social need for further adaptation of VATS is also increasing be 
caused it can reduce the burden on patients. However, the problem of post-operative 
adhesions with VATS has also been reported (15, 49, 50). In VATS where surgical 
procedure is limited, it is expected that the existence of adhesions will be more 
problematic than thoracotomy in securing a surgical field. Along with further expansion 
of operation using VATS, an increase in the demand for re-operative surgery using 
VATS is well anticipated. But there is a concern that the existence of post-operative 
adhesions will inhibit various types of procedures such as hemostasis, blunt dissection, 
and therefore, its prevention is considered to be an important challenge to overcome the 
problems for the development of VATS. If an insoluble hyaluronic acid can prevent 
post-thoracotomy adhesion in VATS, it can greatly contribute to the development of 
VATS. However, insoluble hyaluronic acid is not resistant to damage by rigid 
instruments such as tweezers or clamps by forceps, and hence, its operability is of a 
concern in surgeries that require special steel appliances, and involve small incision 
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wound such as with VATS. Therefore, in Chapter 3 the post-operative adhesion 
prevention effect and operability of insoluble hyaluronic acid membrane were examined 
in a limited field of VATS, and not on regular thoracotomy. 
In Chapter 4 the detection method of the adhesion prevention effect after 
thoracotomy was examined. Thoracotomy in dogs is used in various diseases such as 
mitral valve replacement for treating mitral regurgitation (51), pericardial effusion (52), 
lung tumor (53) and lobular torsion (54). Dogs are expected to receive advanced 
medical treatment as companion animals of human, and the number of opportunities for 
dogs with pleurodesis requiring thoracotomy is expected to increase in the future. The 
presence or absence of pleurodesis and the site of adhesion in dogs prior to thoracotomy 
are important in to those who are considering the treatment options. To find out the 
preventive effect of insoluble hyaluronic acid on post-thoracotomy adhesion examined 
in Chapter 2 and 3, an examination method which is minimally invasive, with high 
safety and simple operability is essential. CT exams are known to be effective detection 
methods of human pleural adhesions (55). Unlike human, it is difficult to adjust the 
breathing of dogs, thus general anesthesia is required for a CT scan. However, dogs that 
need re-thoracotomy often exhibit unstable respiration, and it is risky to perform general 
anesthesia only for examinations. In addition, it is difficult to obtain the dog owner's 
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informed consent. Therefore, the present study focused on ultrasonic examination (56), 
which is known as an alternative examination method of pleural adhesions in humans. 
Ultrasonography is minimally invasive and is trusted as a method for detecting pleural 
adhesions in human (56). However, since the shape of the thorax is different between 
dogs and human, it is impossible to use the human ultrasonic pleurodesis detection 
method in dogs. Therefore, the present study examined whether the human 
ultrasonography can be applicable to that of dogs, as well as any modifications that 
should be made on the test method. Hence, the lung sliding of a dog was observed using 
ultrasonography in mode B, and methods of detecting adhesion between the parietal 
pleura and pulmonary pleura that align with the shape of a dog’s thorax were examined. 
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Chapter 3 
Development of an Anti-Adhesive Membrane for Use  
in Video-Assisted Thoracic Surgery 
 
Introduction 
In chapter 2, the factors controlling the degradation rate of hyaluronic acid, as well 
as the degradation process, was elucidated the shape will be maintained without 
degradation in simulated body fluid for about seven days, and the period of time during 
which adhesions form postoperatively. In this chapter, the application of the insoluble 
hyaluronic acid membrane for video-assisted thoracic surgery (VATS) was evaluated. 
VATS which has become more common in recent years as a minimally invasive 
treatment approach, is now adapted in a variety of procedures including respiratory 
surgery and cardiac surgery, and its problems with postoperative adhesions are also 
described in VATS (15, 49). The surgical manoeuvers available in VATS are restricted, 
and the presence of adhesions is predicted to be a severe problem, because the surgical 
field of view is limited compared with thoracotomy. By further application of VATS to 
various kinds of operative procedures, an increase in demand for repeated operations 
under VATS procedure may be expected. Although VATS is less invasive and causes 
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less postoperative adhesions than standard thoracotomy, still any small adhesion may 
interrupt the operation. From the standpoint of VATS development in the future, the 
prevention of postoperative adhesions should be the major challenge. It is predicted that 
materials highly effective in preventing postoperative adhesions after thoracic surgery 
can be used in VATS with a small incision of about 3-6 cm (66), which will become 
essential in cardiac and respiratory surgeries. In the author’s previous study, when a 
large incision was made in situations such as thoracotomy, it was able to cover the 
whole target site by inserting the membrane into the thoracic cavity after gently folding 
the test membrane in half. It can be spread with gauze balls. However, because the 
membrane was not strong enough to withstand damage caused by solid instruments 
such as tweezers and forceps, their mactical use in VATS surgery needs to be evaluated. 
Thus, in Chapter 3, this study examines the operability, safety, and efficacy of an 
anti-adhesive insoluble hyaluronic acid membrane in VATS.  
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Materials and Methods 
This study was approved by the Institutional Animal Care and Use Committee of 
Tokyo University of Agriculture and Technology (Permit number 27-36). All treatments 
involving experimental animals were conducted in accordance with the Animal 
Experiments Subcommittee of Tokyo University of Agriculture and Technology and the 
Guide for the Care and Use of Laboratory Animals Eighth Edition (Committee for the 
Update of the Guide for the Care and Use of Laboratory Animals; National Research 
Council). 
Test membrane implantation 
Ten male TOYO beagles (9.8-10.5 kg) were purchased from Kitayama Labs Co. 
Ltd. (Nagano, Japan). The experiment consisted of two groups: the experimental group 
and the control group (n=5 each). Animals were given cefovecin sodium (8 mg/kg, sc; 
Convenia®, Zoetis Japan Inc., Tokyo, Japan) to prevent infection and buprenorphine 
(0.02 mg/kg, sc; Buprenorphine for injection 0.2 mg, Nissin Pharmaceutical Co., Ltd., 
Tokyo, Japan) for analgesia. Subsequently, animals were pre-treated with atropine 
sulphate, butorphanol tartrate (0.2 mg/kg, iv; Vetorphale®, Meiji Seika Pharma Co., Ltd., 
Tokyo, Japan), and midazolam (0.2 mg/kg, iv; Midazolam injection [SANDOZ], 
Sandoz K.K., Tokyo, Japan), followed by general anaesthesia induction with propofol (6 
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mg/kg, iv; “Mylan,” Mylan Inc., Tokyo, Japan). Following tracheal intubation, 
anaesthesia was maintained with isoflurane inhalation (1-2%, Isoflurane for animals, 
Intervet K.K., Tokyo, Japan). Respiratory management was performed with manual 
bag-mask ventilation and intermittent positive pressure breathing through an artificial 
anaesthesia device.  
An insoluble hyaluronic acid membrane containing glycerol was used as the test 
membrane (100 mm x 100 mm x 1.0 mm). The test membrane was implanted in the left 
thoracic cavity of the animal under VATS. A 12-mm-diameter port was created at the 
tenth intercostal space on the left side with a trocar, and a 35-mm-diameter small 
incision for operation was subsequently created at the fifth intercostal space on the left 
side under video camera monitoring. A wound protector (for 35-mm-diameter incisions) 
(Wrap Protector FF0707, Hakko Co., Ltd., Nagano, Japan) was inserted at the small 
incision for operation. Intercostal nerve block was performed in advance with 
bupivacaine (Marcaine injection 0.5%, AstraZeneca plc, Osaka, Japan) for port and 
small incision sites. An automatic suture device (Endo GIA, 45 mm, Covidien Japan 
Inc., Tokyo, Japan) was inserted from the port at the tenth intercostal space. Grasping 
forceps were then inserted from the small incision to hold the lung parenchyma, and the 
automatic suture device was used for stapling and dissection. Then, dissected lung tissue 
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was removed from the small incision. In the experimental group, after the 
adhesion-preventing membrane was inserted from the small incision and placed 
between the visceral pleura and parietal pleura, a drain tube (Phycon tube SH No.3: 2.5 
mm inner diameter, 4.0 mm outer diameter, Fuji Systems Corporation, Tokyo, Japan) 
was inserted. After gradually re-expanding the lung lobes, the trocar was removed. The 
wound was closed using 2/0 synthetic absorbable suture (Biosyn, Covidien Japan Inc.) 
using a conventional method. For the control group, a similar procedure was used 
without inserting the adhesion-preventing membrane, and the wound was subsequently 
closed.  
Any abnormalities such as pneumothorax and pleural effusion were checked on the 
day after surgery. Pleural effusions were removed, if present, once a day, and their 
volumes were recorded. Chest drains were removed when pleural effusions were no 
longer observed.  
At postoperative week 2, animals were anaesthetized similarly to the operation for 
membrane insertion and then euthanized with an overdose of potassium chloride 
solution under deep general anaesthesia. Subsequently, blood was removed, and the 
chest was re-opened with median sternotomy.  
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4.2. Observation and test methods 
In all animals, general condition, appetite, and vigour were checked and recorded 
once a day (animals were observed before implantation and after awakening from 
anaesthesia on the day of implantation). The day of implantation was specified as day 1 
of observation.  
At the time of sacrifice when the chest was re-opened, adhesions, if present, were 
dissected macroscopically using Kelly forceps, Metzenbaum scissors, and cotton swabs, 
and the strength of adhesion was evaluated and scored based on the degree of bluntness 
or sharpness of the dissection process (0=no need to dissect; 1=film-like adhesion, can 
be dissected easily; 2=mild adhesion, can be dissected; 3=moderate adhesion, difficult 
to dissect; 4=strong adhesion, impossible to dissect).  
For histological examination, parietal pleura and lung samples were collected near 
the test membrane insertion site. Removed pleural and lung tissues were fixed in 10% 
neutral buffered formalin solution for one week at room temperature. After fixation, 
intercostal tissues were cut perpendicularly from the parietal to the visceral direction to 
create slice tissue samples that were embedded in paraffin blocks. After sectioning, 
samples were stained with hematoxylin and eosin (HE). Under an optical microscope, 
histopathological lesions were categorized according to the criteria for histopathological 
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classification described below, and images of a representative view for each finding 
were taken. To compare the effects of the test membrane in preventing adhesions, the 
adhesion site and dorsal aspect of the lungs (including visceral pleura) were 
histopathologically evaluated in terms of tissue adhesion, fibrosis, mesothelial cell 
hypertrophy, cuboidal epithelialization of type II alveolar epithelial cells, and 
mononuclear cell infiltration, in animals with adhesions between the lung and chest wall 
and in animals with interlobular adhesions. In animals without adhesions, the dorsal 
aspect of the lungs (including visceral pleura) was similarly evaluated.  
The criteria for histopathological classification were the following: (adhesion: –, 
absent; +, present), (fibrosis in pleura: +, localised; ++, diffuse), (mesothelial cell 
hypertrophy in pleura: –, absent; +, mild), (alveolar epithelial cell cuboidal 
epithelialization in alveoli: –, absent; +, localised; ++, diffuse), (mononuclear cell 
infiltration in alveoli: –, absent; +, localised), and (mononuclear cell infiltration in 
interstitium: –, absent; +, localised; ++, diffuse). 
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Results 
Insertion of an adhesion prevention membrane 
After immersion in saline, the membrane became rapidly and sufficiently pliable, 
and it was not cracked by normal handling. In one animal (E4), the membrane was torn 
into multiple pieces while delivering it from the small ~3.5-cm incision for left-sided 
VATS to the thoracic cavity, making it difficult to completely cover the target site. 
Membrane insertion in all other animals in the experimental group was achieved 
successfully (Figure 3-1). Moreover, there were no differences in operability with wet 
gloves or with a wet wound protector placed at the small incision site. The membrane 
did not hinder the chest closing procedure.  
 
Postoperative general condition 
All animals showed satisfactory awakening from anaesthesia. No abnormalities in 
general condition, such as vigour, appetite, and respiratory condition, were observed 
during follow-up. Chest drains were removed when pleural effusions were no longer 
observed (observation days 2-3). 
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Figure 3-1. Membrane insertion procedure 
In the experimental group, the adhesion-preventing membrane is inserted from the small 
incision and placed between the visceral pleura and parietal pleura. Membrane insertion 
in all animals except for E4 in the experimental group was achieved successfully in the 
order of panel A to panel D. 
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Macroscopic findings after thoracotomy 
In the experimental group, adhesions were observed between the chest wall and 
lungs in 2/5 animals, and blunt dissection of the adhesions was difficult to achieve in 
one animal (E4) (adhesion scores: 3 for E4, 0 for E5, 2 for E6, 0 for E7, and 0 for C10). 
Pulmonary interlobular adhesions were observed in 2/5 animals, but blunt dissection 
could be achieved in all adhesions (adhesion scores: 0 for E4, 0 for E5, 0 for E6, 2 for 
E7, and 2 for E10). The median adhesion score was 0. In the control group, adhesions 
were observed between the chest wall and lungs in 3/5 animals, and blunt dissection of 
the adhesions was difficult to achieve in one animal (C2) (adhesion scores: 0 for C1, 3 
for C2, 0 for C3, 1 for C8, and 1 for C9). Interlobular adhesions were observed in all 5/5 
animals, and blunt dissection was difficult to achieve in 4 animals (adhesion scores: 3 
for C1, 3 for C2, 2 for C3, 4 for C8, and 3 for C9). The median adhesion score was 2.5 
(Table 3-1). In both the implant group and the control group, adhesions were completely 
absent at the VATS insertion port (tenth dorsal intercostal space).  
With regard to pleural effusions, 4/5 animals in the experimental group (excluding 
E4) showed pale yellow, viscous pleural effusions (90-110 mL/dog) (Figure 3-2). 
Pleural effusions were not observed in the control group. 
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Table 3-1. Macroscopic findings of adhesion after thoracotomy 
  Control group Experimental group 
No. of animals examined 5 5 
Adhesion score   
 Between the chest wall and lungs 
(1/2/3/4) 
3 (2/0/1/0) 2 (0/1/1/0) 
  
Pulmonary interlobular adhesions 
(1/2/3/4) 
5 (0/1/3/1) 2 (0/2/0/0) 
Median adhesion score 2.5 0.0 
Adhesion scores: the degree of bluntness or sharpness of the dissection process (0, no 
need to dissect; 1, film-like adhesion, can be dissected easily; 2, mild adhesion, can be 
dissected; 3, moderate adhesion, difficult to dissect; 4: strong adhesion, impossible to 
dissect). 
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Figure 3-2. Pleural effusions observed at the re-thoracotomy 
Four out of five animals in the experimental group (excluding E4) showed pale yellow, 
viscous pleural effusions (90-110 mL/dog). 
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Histopathological evaluation 
There were no obvious difference between the experimental group and the control 
group in the incidence or severity of adhesion of lung and chest wall, pulmonary 
interlobular adhesion, pleura fibrosis (Figure. 3-3A and B), pleura mesothelial cell 
hypertrophy (Figure. 3-3C and D), alveolar epithelial cell cuboidal epithelialization 
(Figure. 3-3E and F), alveolar mononuclear cell infiltration (Figure. 3-3E and F), and 
interstitial mononuclear cell infiltration (Table 3-2). 
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Figure 3-3. Histopathological changes in the chest wall and lungs at the 
re-thoracotomy 
The test membrane elicits only a minor inflammatory response and foreign body 
reaction compared with the control group. (A, B) Pleural fibrosis (++) in a control 
animal (A) and an experimental group animal (B). (C, D) Mesothelial cell hypertrophy 
(+) in a control animal (C) and an experimental group animal (D). (E, F) Alveolar 
epithelial cell cuboidal epithelialization (+) and mononuclear cell infiltration (+) in a 
control animal (E) and an experimental group animal (F). 
(A–F: Hematoxylin and eosin staining. Bar: A, B = 200 μm, C–F = 50 μm. 
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Table 3-2. Incidence of histopathological changes appeared in the left lung and left 
chest wall 
  Control group Experimental group 
No. of animals examined 5 5 
Adhesions 
  
 
Lung and chest wall (+) 1 (1) 2 (2) 
  Pulmonary interlobular (+) 3 (3) 2 (2) 
Pleura 
  
 
Fibrosis (+/++) 5 (2/3) 5 (0/5) 
  Mesothelial cell hypertrophy (+) 4 (4) 5 (5) 
Alveoli 
  
 
Epithelial cell cuboidal 
epithelialization (+/++) 
3 (3/0) 5 (4/1) 
  Mononuclear cell infiltration (+) 3 (3) 1 (1) 
Interstitium 
  
 
Mononuclear cell infiltration (+/++) 4 (4/0) 3 (2/1) 
Criteria for histopathological classification: Adhesions: +, present; Fibrosis in the 
pleura: +, localised; ++, diffuse; Mesothelial cell hypertrophy in the pleura: +, mild; 
Alveolar epithelial cell cuboidal epithelialization: +, localised; ++, diffuse; Alveolar 
mononuclear cell infiltration: +, localised; Interstitial mononuclear cell infiltration: +, 
localised; ++, diffuse. 
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Discussion 
One of the major differences between thoracotomy and VATS is the size of the 
incisions associated with the surgery. VATS is a minimally-invasive procedure that 
involves small incisions; for instance, the incision size to remove resected lung lobes is 
limited to 3-6 cm (66). In surgical treatment using anti-adhesive membranes under 
VATS, the insoluble hyaluronic acid membrane becomes flexible for easy handling with 
a high moisture content by immersing it in saline immediately before use. However, it 
can be cracked and torn into multiple pieces if it is completely folded; thus, it is not 
practical to fold the membrane prior to insertion through the small incision. In fact, in 
one animal of the experimental group (E4), the membrane tore into several pieces 
during its delivery from the small incision to the thoracic cavity, and complete coverage 
of the target site could not be achieved. However, it was possible to insert the test 
membrane by grasping the four corners of the test membrane. With this procedure, the 
membrane forms a drawstring pouch and can be dropped into the thoracic cavity by 
pushing the centre of the membrane into the thoracic cavity, without folding it from the 
small incision. Similar to the procedure for thoracotomy, the membrane could cover the 
target site successfully in the thoracic cavity using standard surgical instruments. 
Although it is necessary to have some experience to insert the membrane from a small 
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incision, the technique does not require strict skill. The membrane can also be placed 
successfully by inserting and simply “dropping” it into the thoracic cavity. Moreover, 
this procedure can be achieved with both wet and dry surgical instruments and gloves. 
The membrane showed adhesion-preventing effects simply by placing the membrane 
without attachment to wrap the target site. From this point of view, this membrane was 
superior to the carboxymethyl-cellulose membrane for laparoscopy use. The size of the 
small incision created in the present study (~3.5 cm) was similar to the typical size of 
incision that is created to remove pulmonary lobes in clinical lobectomy (66), indicating 
that this membrane can be used in a practical manner in VATS in the clinical setting.  
In the experimental group, only one animal (E4) developed an adhesion (left chest 
wall and lung) with an adhesion score of 3 (blunt dissection of the adhesion difficult to 
achieve), which can be clinically problematic with VATS. In this animal, the test 
membrane cracked during insertion, and was torn into multiple pieces. The reason for 
the development of the clinically problematic adhesion was insufficient coverage of the 
target site. This animal did not show a pleural effusion at sacrifice. This was because the 
test membrane was manufactured by applying surface water induction technology, 
which enables integration of water by glycerol and then absorption of a large amount of 
water by insoluble hyaluronic acid to create a barrier (25). Consequently, this physical 
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property of this test membrane enables prevention of adhesions between the chest wall 
and lung. As possible causes of the development of adhesions, the test membrane may 
lose its physical properties as a barrier. By cracking the membrane during insertion, this 
membrane loses its surface water induction property, and the uncovered portion may 
develop adhesion. In fact, adhesions were completely absent at the left-sided VATS 
insertion port (tenth dorsal intercostal space) in both the implant and control groups. 
The lack of apparent adhesion at the insertion port may be due to extremely active lung 
movement by respiration and the extremely small incision.  
In the macroscopic examination at sacrifice, no exudative changes suggestive of 
inflammatory responses were observed in the thoracic cavity in the experimental group. 
Histopathological analysis also showed no apparent induction of inflammatory changes 
or a foreign body reaction. This result suggests that the test membrane dissolves 
spontaneously within the thoracic cavity to be absorbed into the body and does not 
remain as a foreign substance, thus not causing an inflammatory response or foreign 
body reaction. Although the chest drain was removed a few days postoperatively when a 
pleural effusion was no longer observed, a pale yellow pleural effusion (90-110 
mL/dog) was observed in 4/5 animals in the experimental group at sacrifice. This pale 
yellow pleural effusion might be generated during the process to dissolve and absorb the 
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test membrane. In human medicine, the clinical symptoms of pleural effusions are 
considered to be dependent on the underlying lung disease (67-69), and the pleural 
effusion observed in the present study would be unlikely to become a problem in the 
clinical setting.  
The extent of surgical invasiveness is one of the important issues that must be 
addressed. While postoperative adhesions after thoracic surgery occurs at a high rate 
(5-7, 9), the incidence of adhesions depends on the intraoperative invasiveness of the 
surgical procedure. In the present study, only wedge resection of the lung lobe was 
performed using an automatic suture device. In this procedure, intraoperative tissue 
dissection was not necessary, and only a small amount of bleeding can be expected with 
this procedure. This is the reason for the fewer adhesions that occurred even in the 
control group and VATS is less invasive than thoracotomy. As future investigations, 
induction of adhesions will need to be compared between use and non-use of the test 
membrane in surgeries with a greater degree of invasiveness, such as lobectomy or 
pericardial incision, instead of wedge resection.  
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Conclusions 
In conclusion, the test membrane used in this study showed satisfactory operability 
not only in typical thoracotomy, but also in VATS, which is becoming increasingly 
common. Its easy delivery and spread within the thoracic cavity may be well suited for 
VATS procedures. This test membrane elicited only a minor inflammatory response and 
foreign body reaction and appears to be practical as a material to prevent postoperative 
adhesions after thoracic surgery and VATS. 
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Chapter 4 
Utility of lung ultrasound for detection of pleural adhesions in dogs 
 
Introduction 
 
In chapter 2, it was elucidated the time-dependent degradation process in insoluble 
hyaluronic acid formulations with a controlled degradation rate. In chapter 3, it was 
indicated that the novel anti-adhesive membrane was effective and safety in preventing 
pleural adhesions. In this chapter, the new method for detecting pleural adhesion after 
thoracic surgery was evaluated. 
There is a high incidence of pleural adhesions after thoracic surgery or in thoracic 
diseases such as lung cancer (70) and lung abscess (71). Although it is uncommon for 
pleural adhesions to cause organ disorders in humans (72), increased risk during 
thoracotomy is one of the significant problems in patients with pleural adhesions. 
Specifically, it has been known in humans for many years that prolonged duration of 
surgery, increased blood loss, poor field of view, and pulmonary vascular injuries occur 
due to postoperative adhesions between the thoracic wall and the lung(5-9). 
Thoracotomy is also performed in dogs to treat various conditions such as mitral 
regurgitation (51), pericardial effusion (52), lung tumor (53), and lung lobe torsion (54). 
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As members of a family, dogs have come to undergo advanced medical treatments, and 
an increasing number of thoracotomies may be predicted in dogs with pleural adhesions 
in the future. Preoperative identification of the presence and location of pleural 
adhesions is essential for a safe approach in canine thoracotomy. A minimally-invasive 
approach such as video-assisted thoracic surgery (VATS) has also become popular in the 
veterinary field (73, 74), and the preoperative detection of pleural adhesions is 
extremely useful, since it is crucial to ensure the surgical field of view in this procedure 
(75). 
Some of the desired features of a procedure for detecting these pleural adhesions 
include minimal invasiveness, high safety, and simple yet convenient operability. One of 
the useful methods for detecting pleural adhesions in humans is computed tomography 
(CT) (55). CT uses a computer to process tomographic images, allowing for 
three-dimensional visualization of the intrathoracic condition. However, there are 
several issues with CT examinations. Reports have shown that human patients, as well 
as some dogs, with a history of interventional vascular embolization (coils) are at higher 
risk of inaccurate diagnosis as a result of metal artifacts (76). CT has also been reported 
to cause pacemaker malfunction in humans (77), and this complication may occur in 
veterinary medicine. CT scanners are unfamiliar to primary veterinary care facilities, 
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and facilities that can own such equipment are limited. Even for facilities with CT 
scanners, proper interpretation of the results requires extensive training. 
Ultrasound examination is another method that can be used for the assessment of 
pleural adhesions in humans (56). It has been reported to be safe, effective, 
cost-effective, and particularly useful in preoperative examinations for VATS in humans 
(78, 79). In addition, the adhesions can be evaluated with B-mode only, without Doppler 
function, and ultrasound examinations are available at primary care facilities and small 
clinics. Furthermore, advanced interpretation skills are not necessary, since it is only 
used to confirm the presence or absence of lung sliding. However, the ultrasound 
method to identify human pleural adhesions cannot be applied directly to dogs due to 
differences in the shape of the thorax between dogs and humans. 
In the present study, lung respiratory movement (“lung sliding”) was examined in 
dogs using B-mode on ultrasound, and a method that assesses adhesions between the 
parietal pleura and the lung (pulmonary pleura), adjusting for the shape of the canine 
thorax, was evaluated. The results and the effectiveness of lung ultrasound are 
presented. 
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Materials and Methods 
This study was approved by the Institutional Animal Care and Use Committee of 
Tokyo University of Agriculture and Technology (Permit number 27-36). All treatments 
in experimental animals were conducted in accordance with the Regulations on Animal 
Experiments of Tokyo University of Agriculture and Technology and the Guide for the 
Care and Use of Laboratory Animals Eighth Edition (Committee for the Update of the 
Guide for the Care and Use of Laboratory Animals; National Research Council). 
First, lung ultrasound was performed under general anesthesia, followed by 
thoracotomy. Two weeks after thoracotomy, lung ultrasound was repeated under general 
anesthesia. Subsequently, the animals were sacrificed, and thoracotomy was again 
performed to determine the status of pleural adhesions. The detailed procedure is 
described below. 
 
Animal Preparation 
Seventeen male beagles (TOYO Beagles; KITAYAMA LABES, Nagano, Japan) 
were used in this study. 
 
Anesthesia 
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The animals were given cefovecin sodium (8 mg/kg, sc; Convenia, Zoetis Japan 
Inc., Tokyo, Japan) to prevent infection and buprenorphine (0.02 mg/kg, sc; 
Buprenorphine for injection 0.2 mg, Nissin Pharmaceutical, Tokyo, Japan) for analgesia. 
Subsequently, the animals were pre-treated with atropine sulfate, butorphanol tartrate 
(0.2 mg/kg, iv; Vetorphale R, Meiji Seika Pharma Co., Ltd., Tokyo, Japan), and 
midazolam (0.2 mg/kg, iv; Midazolam injection [SANDOZ], Sandoz, Tokyo, Japan), 
followed by propofol (6 mg/kg, iv; “Mylan,” Mylan Inc., Tokyo, Japan) for induction of 
general anesthesia. Following tracheal intubation, anesthesia was maintained with 
isoflurane inhalation (1-2%, Isoflurane for animals, Intervet K.K., Tokyo, Japan). 
Respiratory management was performed with intermittent positive pressure ventilation 
through an artificial anesthesia device. During lung ultrasound examination, the 
inspiratory pressure was set at 20 mmHg to induce exaggerated respiration under forced 
ventilation with a respiratory rate of 12 breaths per minute and I (inspiration):E 
(expiration)=1:1, but without positive end-expiratory pressure (PEEP). 
 
Ultrasound Scanning 
Lung sliding assessments and adhesion examinations were performed using lung 
ultrasound. This method has been patented in Japan (PATENT NUMBER 6115958). 
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After anesthesia induction, lung ultrasound examination was performed in a general 
operating room. The presence or absence of adhesions was determined noninvasively 
using an F75 ultrasound system (Hitachi Aloka Medical, Ltd, Tokyo, Japan) and a linear 
probe (Aloka UST-5412, center frequency of 12 MHz, adjustable frequency range of 10 
to 14 MHz). To examine pleural adhesions on the left side, the animal was placed in a 
right lateral recumbent position and shaved from the first to thirteenth rib on the left 
thoracic wall. Similarly to a previously reported method (79, 80), B-mode was used, and 
the probe was pressed perpendicularly to the left thoracic wall such that the reference 
marker faced the caudal side. The probe was kept in a fixed position when placed on the 
chest of the dog. To examine adhesions on the right side, the animal was placed in a left 
lateral recumbent position, and the probe was pressed perpendicularly to the right 
thoracic wall in a similar manner as above (Figure 4-1).  
The sites observed were the third to sixth intercostal spaces of the thoracic wall on 
both sides at the dorsal line (at the kidney level) and at the ventral line (approximately 5 
cm dorsal to the costochondral joint). A total of 16 sites (8 on each side) per animal 
were examined. 
The pleural movements of two consecutive respirations were recorded in the format 
of still images and videos. The presence or absence of adhesions was determined based  
 53 / 98 
 
 
 
 
Figure 4-1. Examining adhesions on the left side 
The animal is placed in a right lateral recumbent position, and the probe is pressed 
perpendicular to the left thoracic wall. 
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on the presence or absence of sites that showed disappearance of respiratory movement 
(lung sliding) of the parietal pleura and visceral pleura. Lung sliding was checked at 
every intercostal space. Lung sliding was scored on a four-level scale based on the 
percentage of the total area that showed lung sliding (3: lung sliding observed in 
roughly 80% or greater of the total area of the intercostal space; 2: movement observed 
in about 50% of the total area of the intercostal space; 1: movement observed in a small 
area of the intercostal space; 0: movement absent) (Figure 4-2). For example, when the 
4th intercostal space was checked at the dorsal line, the probe was kept fixed in the 4th 
intercostal space at the kidney level, and if movement was observed in 80% of the total 
area from the caudal 4th costal to the cranial 5th costal, the lung sliding score was 3. On 
inter-session analysis, the kappa statistic of the lung sliding score was 0.656577, while 
on intra-session analysis (performed by the same assessor on a different day), the kappa 
statistic was 0.866489. With lung sliding scores of 0, 1, and 2, adhesion was considered 
present, while a score of 3 was taken as indicating the absence of adhesion.  
 
Thoracotomy 
After opening the chest with an incision of approximately 10 cm at the fifth 
intercostal space on both sides and exposing the area to air for 30 minutes, an insoluble  
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Figure 4-2. Lung Sliding 
Lung sliding was scored on a four-level scale based on the percentage of the total area 
that showed lung sliding. 
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hyaluronic acid membrane was placed on the visceral pleura of the incision wound to 
prevent adhesions. The chest was subsequently closed using a standard method. 
 
Necropsy 
Two weeks after the initial lung ultrasound and thoracotomy, lung ultrasound was 
again performed under the same anesthesia conditions as the initial thoracotomy before 
sacrifice. The animals were subsequently sacrificed with an overdose of potassium 
chloride (KCL Injection 20 mEq Kit; Terumo Co., Ltd., Tokyo, Japan) under deep 
general anesthesia. Necropsy was performed with a median sternotomy to determine the 
presence or absence of adhesions in the thoracic cavity, and sites with adhesions were 
examined carefully. 
 
Statistical approach 
The presence/absence of adhesions was compared statistically by comparing the 
lung sliding score of the parts with adhesion and the lung sliding score of the parts with 
no adhesion using the Mann-Whitney U test. 
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Results 
Visualization of the pleural line at any examination site was possible in all dogs. 
Visualization of lung sliding was performed by simply pressing the probe vertically 
against the intercostal region, without any additional movement or rotation of the probe 
(i.e. it is necessary to keep it in a fixed position). The lung ultrasound findings were 
compared with adhesion findings at necropsy. The median lung sliding score of the 12 
sites that showed pleural adhesions was 1.5. The median lung sliding score of the 532 
sites that did not show pleural adhesions was 3.0. The lung sliding score was 
significantly lower in the presence of adhesions (P<0.0001, Mann-Whitney test). The 
sites with pleural adhesions observed with thoracotomy coincided with the sites with 
decreased lung sliding scores on lung ultrasound (Table 4-1). 
The sensitivity and specificity for detecting pleural adhesions with the lung sliding 
score were determined. Of the 77 sites with an adhesion determined by a lung sliding 
score of ≤2, adhesions were present in 12 sites and absent in 65 sites on macroscopic 
examination at necropsy. Of the 467 sites without an adhesion, determined by a lung 
sliding score of 3, adhesions were present in 0 sites and absent in 467 sites on 
macroscopic examination at necropsy. Based on these results, the ultrasound 
examination detected pleural adhesions with a sensitivity of 100.0% and a specificity of  
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Table 4-1. Lung sliding scores on lung ultrasound 
  
Macroscopic findings of adhesions 
Present  Not present 
  No. of experimental parts 12 532 
Lung sliding score    
 Intercostal 3 dorsal (0/1/2/3) (0/0/0/0) (0/0/6/62) 
  ventral (0/1/2/3) (0/0/0/0) (0/0/24/44) 
 Intercostal 4 dorsal (0/1/2/3) (0/0/0/0) (0/0/6/62) 
  ventral (0/1/2/3) (0/0/0/0) (0/1/12/55) 
 Intercostal 5 dorsal (0/1/2/3) (0/1/3/0) (0/0/3/61) 
  ventral (0/1/2/3) (0/6/2/0) (0/0/4/56) 
 Intercostal 6 dorsal (0/1/2/3) (0/0/0/0) (0/0/4/64) 
   ventral (0/1/2/3) (0/0/0/0) (0/0/5/63) 
  Total dorsal and ventral (0/1/2/3) (0/7/5/0) (0/1/64/467) 
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87.8%. 
The median lung sliding scores at observed sites without adhesions were: 3.0 at the 
third intercostal space; 3.0 at the fourth intercostal space; 3.0 at the fifth intercostal 
space; 3.0 at the sixth intercostal space; 3.0 at the dorsal side; and 3.0 at the ventral side. 
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Discussion 
In the present study, a high-frequency linear probe was selected for the 
visualization of the pleural line. By angling the reference mark of the probe slightly in 
the dorsocaudal direction rather than straight in the caudal direction, it was easy to 
visualize the pleural line at the third intercostal space of the anterior chest area. 
Moreover, expert skills were not required for the detection of pleural line movement, 
this examination can be easily accomplished in a typical operating room with equipment 
for respiratory management with forced ventilation. The operability was straightforward, 
and the examination itself was simple. 
With pleural adhesions, the lung sliding score on lung ultrasound decreased 
significantly (P<0.0001), with sensitivity of 100% and specificity of 87.8%. These 
results can be explained in the following manner. “Lung sliding,” a term coined by 
Lichtenstein et al., is observed on ultrasound as the movement of parietal pleura and 
visceral pleura that occurs with respiratory motion (81). Lung sliding could be clearly 
observed at sites with active pleural sliding movements that occur with respiration, and 
lung sliding decreased where pleural movement was not active, even at normal sites 
without adhesions. The author initially postulated that decreased lung sliding would be 
observed more on the cranial side than on the caudal side and on the dorsal side more 
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than on the ventral side based on the anatomical structure of the lung. However, every 
median lung sliding score was 3.0 for the third through sixth intercostal spaces and for 
both dorsal and ventral sides. This may have occurred because “the area percentage of 
the observed site in which lung sliding was observed” rather than “how many 
centimeters the observed site shifted in the cranio-caudal direction” was evaluated. In 
other words, if at least 80% of the area within the observed site moved, then the lung 
sliding score would be 3, regardless of actual displacement distance. There is a specific 
reason why the lung sliding scores were classified by percentage of movement area that 
moved rather than by the movement distance. Indeed, there is a report that measured the 
distance of lung sliding movement in chest ultrasound examination of pleural adhesions 
in humans (76). However, unlike humans, dogs vary greatly in size depending on the 
breed, from small dogs such as Chihuahuas to large dogs such as Great Danes. Beagles 
generally have a uniform body size, and their individual differences can be negligible. 
However, considering the clinical application of the present examination method in the 
future, using a classification by the percentage of area that moved rather than by the 
distance of movement would be more practical and appropriate. Based on the above, the 
above-mentioned ultrasound method should be combined with other tests to make a 
definitive diagnosis of the presence of canine pleural adhesions.  
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Because only healthy dogs were tested in a specific breed, future investigations 
should be conducted tests in other breeds and clinical cases. However, this method 
appears to be a highly reliable tool for excluding canine pleural adhesions.  
Ultrasound detection of pleural adhesions may be more useful in dogs than in 
humans. For detecting pleural adhesions using lung ultrasound in humans, the 
sensitivity and specificity were reported to be: 63.6% and 79.4% at the upper thoracic 
area and 81.5% and 81.0% at the lower thoracic area (56); 80.6% and 96.1% (78), 
respectively; and 88.0% and 82.6% (79), respectively. Pleural adhesion examination 
with lung ultrasound in dogs in the present examination resulted in a sensitivity of 
100% and specificity of 87.8%, indicating a greater sensitivity and similar specificity 
compared to the reports in humans. All pleural adhesions in the present study developed 
at the fifth intercostal space along the thoracic wall incision line. The lateral thoracic 
wall at the fifth intercostal space is flat, allowing a relatively easy visualization of the 
lungs on ultrasound, and lung sliding can be examined clearly even in normal lungs at 
this site. This may explain the reasons why favorable results were obtained in the 
present examination. Pleural adhesions caused by surgical damage appear at the incision 
line or the surgically injured site. For example, they occur between the pericardium and 
pleura in surgeries that entail pericardial resection. In the present study, they appeared 
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between the lung (visceral pleura) and the thoracic wall (parietal pleura) at the fifth 
intercostal space. Pleural adhesions caused by endogenous factors, such as lung cancer 
or abscess, develop at these regions. In other words, for future clinical application of the 
present examination method, it is necessary to verify its sensitivity and specificity in 
detecting pleural adhesions at sites other than the fifth intercostal space. In addition, it 
has been reported in humans that lung ultrasound sensitivity is lower in the upper lung 
region than in the lower lung region (56). Thus, it is also necessary for dogs to 
determine whether there are differences between the cranial and caudal sides in the 
sensitivity for detecting pleural adhesions through lung sliding. Furthermore, it is 
essential to verify whether the present examination method can detect canine pleural 
adhesions in conditions such as obesity and emphysema that are known to hinder 
detection of lung sliding (56). In addition, assessment of lung sliding could judge only 
the presence or absence of pleural adhesion in this study. Further study is needed to 
make sure whether a decreased lung sliding score can detect partial pleural adhesions. 
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Conclusions 
In conclusion, the present results showed that the examination of lung sliding by 
thoracic ultrasound has a high diagnostic value for detecting canine pleural adhesions 
and is useful in identifying adhesion sites before thoracic surgery. However, this result 
is limited to healthy dogs. Thus, information about the feasibility and accuracy of this 
technique in pathophysiological models needs to be obtained by further research. 
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Chapter 5 
General Discussion 
 
The objective in Chapter 2 was to elucidate the time-dependent degradation 
process in insoluble hyaluronic acid formulations with a controlled degradation rate. 
Sodium hyaluronate was treated with the conditions under which the treatment time was 
set to every 10 minutes from 0 to 90 minutes, and their IR and swelling rate were 
investigated subsequently. This study suggested that swelling ratio in control can be 
controlled by adjusting the treatment time, and the 1740 cm-1 absorption peak of IR is 
the predictable indicators of swelling rate. Three types of insoluble hyaluronic acid 
membrane with different swelling ratios (three for each type) were created for 
investigation of degradation process. The degradation score and swelling ratio showed a 
strong correlation between each other. Chapter 2 revealed one of controllable factor for 
swelling ratio of hyaluronic acid formulations. It also suggested that the correlations 
between IR absorption peak at 1740 cm-1 and swelling ratio and between IR absorption 
peak at 1740 cm-1 and degradation speed. In addition, it showed that the hyaluronic acid 
formulations is degraded gradually changes with time. Generated hyaluronic acid 
formulations had no byproducts through the generation process. The relationship of 
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insolubilization, swelling rate, and degradation start rate is inferred as follow. 
Functional group of hyaluronic acid was replaced -COONa to -COOH caused by 
treatment with acetic anhydride. Involving this change, intermolecular hydrogen bridge 
was formed and increased insolubilizing. According to reaction time with acetic 
anhydride, the replacement from -COONa to -COOH would be increased. When it was 
degraded, this reaction might be retrograded, and returned to the original -COONa to 
cleave hydrogen bond, then the membrane would probably swell. Therefor the control 
of reaction time might lead to degradation start rate. 
In Chapter 3, the purpose is to test the effectiveness of insoluble hyaluronic acid 
membrane for postthoracotomy adhesion and operability. Using an insoluble hyaluronic 
acid membrane that remains in the surgical wound during the period when postoperative 
adhesions are formed and that has a swelling rate sufficient to maintain its shape as a 
physical barrier, the author tested the postoperative adhesion prevention effect and 
manipulability of the membrane. A previous report showed an effect of preventing 
post-thoracotomy adhesion using glycerin and surface water induction technology as a 
post-thoracic surgery adhesion prevention agent in dogs (25). Insoluble hyaluronic acid 
membranes are not damaged with normal handling but are susceptible to tears, and once 
they are torn, the damage may progress. Although little concern was paid to 
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manipulability in general thoracotomy, its use in thoracoscopic surgery with a small 
incision wound of 3.0 to 6.0 cm has been increasing recently (66). This gives rise to 
more concern about the damage to insoluble hyaluronic acid membranes and reduced 
manipulability as they are introduced into the thoracic cavity through a small incision 
hole. Thus, the small size of the incisions used for VATS (3–6 cm) and the use of 
specialized instruments significantly differe from those used in regular thoracotomy. In 
Chapter 3, whether the test membrane could be easily used under the special conditions 
imposed by VATS was investigated, and the macroscopic and histopathological 
investigations of inflammatory and immunological reactions in VATS were conducted. 
About the operativity of this membrane, membrane insertion in all other animals in the 
experimental group was achieved successfully except for that in one animal, the 
membrane was torn into multiple pieces while delivering from the small ~3.5-cm 
incision for left-sided VATS to the thoracic cavity, making it difficult to cover the target 
site completely. There were no differences in operability with wet gloves or with a wet 
wound protector placed at the small incision site and the membrane did not hinder the 
chest closing procedure. In the experimental group, adhesions were observed between 
the chest wall and lungs in 2/5 animals, and blunt dissection of the adhesions was 
difficult to achieve in the exceptimal animal. Pulmonary interlobular adhesions were 
 68 / 98 
 
 
few and the median adhesion score was 0. In the control group, adhesions were 
observed in all animals, and the median adhesion score was 2.5. In the macroscopic 
examination at sacrifice, there were no inflammatory responses in the thoracic cavity in 
the experimental group. Histopathological analysis also showed no apparent induction 
of inflammatory changes or any foreign body reaction. This result suggests that the test 
membrane dissolves spontaneously within the thoracic cavity and can be absorbed into 
the body which does neither remain as a foreign substance nor cause any inflammatory 
response or foreign body reaction. The issue of this study was surgical invasiveness 
because only wedge resection of the lung lobe was performed using an automatic suture 
device in this study. However, the test membrane used in this study showed satisfactory 
operability in VATS. Following are possible reasons for high postoperative adhesion 
prevention effect obtained with insoluble hyaluronic acid membranes. First is that 
insoluble hyaluronic acid functions as a superior physical barrier. As shown in Chapter 
2, this may be due to the fact that control of the degree of insolubility of hyaluronic acid 
leads to control of the swelling rate, suggesting the creation of an insoluble hyaluronic 
acid membrane with a low swelling rate allows it to function as a physical barrier for 
the necessary postoperative duration. The second reason may be the high 
water-retaining capacity of hyaluronic acid. When hyaluronic acid is hydrolyzed in the 
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body, a large amount of water accumulates in the surrounding area. It is also possible 
that the membrane simultaneously dilutes inflammatory substances produced during 
inflammation. In fact, retention of pleural fluid was seen together with liquefied test 
membranes during autopsy in one of my experimental group in which insoluble 
hyaluronic acid membranes had been introduced. The high biocompatibility and safety 
of hyaluronic acid may also have postoperative adhesion prevention effects. The 
response of hyaluronic acid in vivo differs depending on its molecular weight. Low 
molecular weight hyaluronic acid acts toward the induction of inflammation such as 
lymphocyte rolling via CD44 during inflammation (82), whereas high molecular weight 
hyaluronic acid shows anti-inflammatory activity within the body (83, 84). The 
insoluble hyaluronic acid membrane used as the test membrane in this study has a high 
molecular weight, and so may have acted toward the inhibition of inflammation(49). In 
this Chapter 3, one of limitations is less invasive than clinical cases. Therefore, in future 
investigations, induction of adhesions will need to be compared between use and 
non-use of the test membrane in surgeries with a greater degree of invasiveness, such as 
lobectomy or pericardial incision, instead of wedge resection. 
The objective in Chapter 4 is to confirm whether postoperative adhesions can be 
detected, in case the adhesions cannot be prevented completely. Noninvasive methods 
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of detecting postthoracotomy adhesions in dogs were performed using ultrasonography 
of the lung sliding. The median lung sliding score of the 12 sites that showed pleural 
adhesions was 1.5. The median lung sliding score of the 521 sites that did not show 
pleural adhesions was 3.0. The lung sliding score was significantly decreased in the 
presence of adhesions. The sites with pleural adhesions observed with thoracotomy 
coincided with the sites with decreased lung sliding scores on lung ultrasound. The 
ultrasound examination detected pleural adhesions with a sensitivity of 100.0% and a 
specificity of 87.7%. These results showed that the examination of lung sliding by 
thoracic ultrasound has a high diagnostic value for detecting canine pleural adhesions 
and is useful in identifying adhesion sites before thoracic surgery. 
From the aforementioned series of studies, the present study suggests that the 
following conclusions could be made in regard to the application of insoluble 
hyaluronic acid and its preparations. First, the present study clarified a part of the 
controlling factors of the decomposition rate of hyaluronic acid, and also clarified its 
decomposition process which have not been elucidated so far. It implies that swelling 
rate of the hyaluronic acid preparation can be controlled by changing the 
-COONa/-COOH ratio by changing the insolubilization process duration. Furthermore, 
it was possible to manipulate the decomposition starting time in simulated body fluids 
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by controlling this swelling ratio. Hyaluronic acid used in medicine has various 
requirements such as hardness, viscosity and duration of effect. The hyaluronic acid 
preparation currently being used in vivo primarily manipulates the molecular weight to 
control the duration of effect in vivo (38). Application of the results of the present study 
not only opens the way to develop new processing methods for hyaluronic acid 
preparations, but also creating a variety of hyaluronic acid preparations that have never 
been done. Moreover, by clarifying the required swelling ratio of insoluble hyaluronic 
acid for creating the post-operative adhesion inhibitor, it can not only be used for 
post-thoracotomy adhesion, but also can be expected to be applicable for other diseases 
including joint contracture, via the high adhesion prevention effect. 
Furthermore, the fact that high post-operative adhesion prevention effect was shown 
in a dog open thoracotomy model may change the history of thoracic surgery. The 
worsening of operability and visual clarity during surgery and increase in bleeding due 
to tissue adhesion during a second-time thoracotomy is a post-operative complication 
well known to that all thoracic surgeons. If an operation field similar to the initial 
surgery can be obtained for the re-operation without causing complications, it is 
possible to reduce the burden on the patients and the fatigue of surgeons, thereby 
shortening the hospitalization period and reducing the cost. This is a major benefit for 
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both patients and surgeons. In addition, the fact that the membrane shown to be 
effective in operability is not limited to regular thoracotomy, it can also be applied to a 
special surgical method like VATS that is ensured for future development, shows its 
promising contribution to the development of thoracic surgery. In fact, this is an 
extremely unique post-operative adhesion inhibitor that is comprised of pure hyaluronic 
acid without any impurities, as described in Chapter 2, and is different from 
conventional adhesion inhibitors that is primarily comprised of substances that do not 
exist in vivo (21, 22), and post-operative adhesion inhibitors that are primarily comprised 
of carboxymethyl-cellulose (12, 13) which that are currently frequently used for the 
abdominal area. The fact that the membrane is consisted only of hyaluronic acid, which 
is present in the body and biodegradable, showed a high postoperative adhesion 
prevention effect makes it different from conventional adhesion inhibitors, especially 
from the viewpoint of safety in clinical application. 
Furthermore, being able to demonstrate a non-invasive detection method of 
pleurodesis in dogs in an actual open thoracotomy case for the first time in the world is 
significally meaningful. Although some veterinarians may be able to detect the loss of 
respiratory activity in a lung due to adhesion in the chest area based on one’s own 
experience and knowledge, the present study provided a method that can detect 
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pleurodesis on the basis of measurement data, instead of empirical rule. Moreover, the 
present study suggested that by making a criterion based on the ratio of lung movement 
rather than the ratio of the distance the lung moved like in humans, it suggested a 
method that can be used regardless of the body type or the dog’s breed. Furthermore, 
ultrasonic examinations in a recumbent position can be performed even on a dog under 
a poor respiratory condition, and, dogs may be inspected under the owner's attendance 
or oxygen mask, depending on the condition. Compared with CT examination that 
requires isolation under general anesthesia, the physical and psychological burden of the 
patient is greatly reduced. This detection method not only makes it easy to plan a dog's 
chest re-operation but can also be used for daily examinations due to its 
non-invasiveness and simplicity. A future task of this study, it is essential to verify 
whether the present examination method can detect canine pleural adhesions in clinical 
cases such as obesity and emphysema that are known to hinder detection of lung sliding. 
However, the present study has enabled a new step forward advancing medicine 
through the development of a de novo hyaluronic acid preparation, and provides a 
possibility for a new treatment option for not only thoracic surgery in humans and dogs 
but also in other surgical fields, as well as advancing thoracic surgery and examination 
of dogs. 
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Conclusions 
 
This study elucidated the following points. First, part of the degradation process of 
a hyaluronic acid formulation, which has long remained unclear, was elucidated. The 
swelling rate is controlled by making the formulation insoluble, and the degradation rate 
of hyaluronic acid formulation can be controlled by adjusting the swelling rate. This 
discovery has the potential to change the flow of future developments in hyaluronic acid 
formulations. This is because hyaluronic acid formulations, which have no potentially 
harmful byproducts and for which the residual period in the body can be controlled, are 
effective in preventing post-thoracic surgery adhesions, as well as having other potential 
clinical applications. For example, they are promising for clinical applications to 
prevent joint contracture by introduction into the joint. 
Next, post-thoracic surgery adhesions could be prevented at a high rate in dogs 
with test membranes that used a hyaluronic acid formulation in which the degradation 
rate was adjusted. With this method of preventing post-thoracic surgery adhesions, no 
problems were encountered even when the gloves or equipment were wet. Moreover, 
even thoracoscopic surgery with small incision wounds could be performed without loss 
of manipulability. Compared with the carboxymethyl cellulose membranes currently in 
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wide use as agents for preventing post-abdominal surgery adhesion, hyaluronic acid 
membranes are considered to have superior aspects including both the post-thoracic 
surgery adhesion prevention effect and also manipulability. Moreover, if they are useful 
as a post-thoracic surgery adhesion prevention agent, they will be also obviously 
promising for use as a post-abdominal surgery adhesion prevention agent. 
This study also suggests that the adhesion sites can be detected noninvasively 
when pleural adhesions have developed. In particular, the finding that the presence of 
lung sliding indicates the absence of adhesions at that site is very significant for 
determining the operative procedure before thoracic surgery. These findings are useful 
not only in examining the effectiveness of the test membrane, but also in procedures 
such as determining the incision site in dogs with a history of thoracic surgery or the 
technique for thoracic surgery in dogs with thoracic tumors or other conditions for 
which there is concern regarding thoracic adhesions, even without a history of 
thoracotomy. 
The results of this study make it possible to predict the degradation rate of 
insoluble hyaluronic acid formulations by controlling the swelling rate during 
preparation. The use of insoluble hyaluronic acid formulations will help to prevent the 
blood loss, time loss, and poor visual field that occur with separation of adhering 
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pulmonary lobes from the thoracic wall during repeat thoracotomies. 
The results obstained in this study will also allow the noninvasive, accurate 
prediction of the status of adhesions within the thoracic cavity before visual 
confirmation. In addition to its use as a post-thoracic surgery adhesion prevention agent, 
novel approaches to clinical applications of hyaluronic acid formulations will also 
become possible. These results may contribute to many areas of medicine over a broad 
range, not limited to thoracic surgery. 
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要 旨 
 
胸部術後癒着防止剤に対する需要は高く、現在も数多く研究されているが、
未だ開発途上である。グリセリンを保水剤とした表層水誘導技術の先行研究に
おいて、高い胸部術後癒着防止効果が報告されている。ところがグリセリンは
安全性に対する懸念があるため、より安全性の高いヒアルロン酸を保水剤とし
て、同技術を用いた胸部術後癒着防止剤の開発を行うこととした。 
術後癒着防止剤は癒着が形成される術後約 1 週間、分解されることなく切
開部に留まる必要性がある。ところが、ヒアルロン酸製剤の分解速度制御因子
と分解過程は未解明の部分が多かった。そこで第 2 章では、新規不溶化ヒアル
ロン酸製剤である被験膜を用いて、その分解速度の制御因子および分解過程を
明らかにすることを試みた。ヒアルロン酸ナトリウムを不溶化処理し、不溶化
処理時間が異なる 3タイプの被験膜を作製した後、それぞれの分子構造を FT-IR
を用いて分析した。さらに、擬似体液中での被験膜の経時的な形状変化につい
てもスコアリングした。その結果、不溶化処理時間を変化させることで、被験
膜の膨張率と分解開始時間を制御可能であることが判明した。さらに、その分
解過程についても明らかにすることができた。 
第 3 章では、被験膜による胸部術後癒着防止効果とその操作性、炎症性と
異物反応について、近年その利用が拡大している胸腔鏡手術において検証した。
被験膜は胸腔内に問題なく挿入可能であり、手袋が濡れていてもその操作性は
変わらなかった。実験群の癒着スコア中央値は 0 であり、コントロール群の癒
着スコア中央値は 2.5であった。肉眼的所見では、実験群で炎症反応はみられず、
病理組織学的にも被験膜に対する明らかな炎症反応、異物反応は認められなか
った。正常犬の肺葉部分切除は、疾患を有する臨床症例と比較して侵襲が低い
という課題はあるが、被験膜は胸腔鏡手術において有用であることが示唆され
 95 / 98 
 
 
た。 
第 4 章では、胸部術後癒着の非侵襲的検出の可否を目的とした。犬で超音
波装置を用い、Lung Sliding（LS）の観察による胸部術後癒着の非侵襲的な検出
方法について検証した。胸膜癒着が存在する 12ヶ所の LS スコアは 1.5であり、
胸膜癒着の存在しない 521ヶ所の LS スコアは 3.0であった。LS は癒着部位で顕
著に減少しており、超音波検査後に開胸下で確認した胸膜癒着発生部位と LS ス
コア低下部位は一致していた。本検査法による胸膜癒着検出は、感度 100.0%、
特異度 87.7%であった。この結果から、本法は犬における胸膜癒着部位特定に有
用であると考えられた。 
本研究において、長らく未解明であったヒアルロン酸製剤の分解過程の一
端を解明し、また、被験膜は犬の胸部術後癒着防止に有用であると考えられた。
さらに、胸膜癒着発生時も、その非侵襲的検出が可能であると示唆された。こ
れらから、胸部術後癒着防止剤としての有用な素材の開発とその有用性の非侵
襲的検出方法確立にとどまらず、ヒアルロン酸製剤の臨床応用に対するこれま
でにない利用方法の可能性を開拓できたと考えられる。 
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Abstract 
 
There is a high demand for agents that prevent adhesions following thoracic 
surgery. While several studies of such agents are presently underway, they are still very 
much under development. A previous study found that surface water induction 
technology using glycerin as the humectant was highly effective for preventing 
postthoracotomy adhesions. However, as the safety of glycerin raises concerns, I 
decided to develop a postthoracotomy adhesion preventive agent using the same 
technology but with hyaluronic acid, a safer choice, for the humectant. 
  Postoperative adhesion preventive agents need to stay in the incision area 
without being dissolved for approximately one week postoperatively, which is the 
period when adhesions form. However, factors that control the degradation rate and 
process of hyaluronic acid are largely unknown. Therefore, in chapter 2, I attempted to 
elucidate factors that control the degradation rate and degradation process of hyaluronic 
acid using test membranes from a new insoluble hyaluronic acid preparation. Sodium 
hyaluronate was treated to become insoluble, and after preparing three types of test 
membranes with different insolubilization treatments, the molecular structure of each 
was analyzed using Fourier-transform infrared spectroscopy (FT-IR). Morphological 
changes over time of the test membranes in simulated body fluid were also scored. As a 
result, I found that the expansion rate of the test membrane and the time when it starts to 
degrade could be controlled by changing the insolubilization treatment duration. 
Furthermore, I was able to clarify the degradation process. 
  In chapter 3, I examined the postthoracotomy adhesion prevention effect and 
related operability of the test membranes, as well as inflammatory and foreign body 
reaction in thoracoscopic surgery, for which the test membrane has gained popularity in 
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recent years. The test membrane can be inserted into the pleural cavity without any 
problem, with no change to operability even if the surgeon’s gloves become wet. The 
median score for adhesions was 0 in the experiment group, and 2.5 in the control group. 
Macroscopic findings revealed no inflammatory reaction in the experiment group. 
Histopathologically, there was no clear inflammatory reaction or any foreign body 
reaction to the test membranes. For partial lobectomy in normal dogs, minimal 
invasiveness is a challenge compared to in clinical cases with disease. My results 
suggested that the test membrane is useful for thoracoscopic surgery. 
  In chapter 4, I aimed to determine the advantages and disadvantages of 
non-invasive detection of postthoracotomy adhesions. I investigated a noninvasive 
method of detecting postthoracotomy adhesions by lung sliding (LS) observation using 
ultrasonography in dogs. The LS score of 12 sites with pleural adhesions was 1.5, and 
the LS score of 521 sites without pleural adhesions was 3.0. LS was remarkably reduced 
at adhesion sites, and the sites with pleural adhesion confirmed by thoracotomy after 
ultrasound examination were consistent with the sites with low LS scores. Pleural 
adhesion detection using the present test method had sensitivity of 100%, and 
specificity of 87.7%. Therefore, it appears that this method is useful for identifying 
pleural adhesion sites in dogs. 
  In the present study, I clarified one part of the degradation process of hyaluronic 
acid, which had long been unclear. I also found that the test membrane was useful for 
preventing postthoracotomy adhesions in dogs. Moreover, results suggested that even in 
the event of pleural adhesion onset, the adhesions can be detected non-invasively. 
Therefore, it appears that I developed a useful postthoractomy adhesion preventive 
agent that could aid in establishing an effective noninvasive method of detecting 
adhesions. My method could also open up novel methods of utilization of hyaluronic 
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acid preparations for clinical application. 
 
 
